Agenus Inc. (AGEN)
NASDAQ: AGEN · Real-Time Price · USD
5.95
+0.79 (15.31%)
At close: Jun 6, 2025, 4:00 PM
6.05
+0.10 (1.68%)
After-hours: Jun 6, 2025, 6:50 PM EDT
Agenus Revenue
Agenus had revenue of $24.07M in the quarter ending March 31, 2025, a decrease of -14.07%. This brings the company's revenue in the last twelve months to $99.52M, down -38.34% year-over-year. In the year 2024, Agenus had annual revenue of $103.46M, down -33.81%.
Revenue (ttm)
$99.52M
Revenue Growth
-38.34%
P/S Ratio
1.17
Revenue / Employee
$314,949
Employees
316
Market Cap
163.13M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 103.46M | -52.85M | -33.81% |
Dec 31, 2023 | 156.31M | 58.29M | 59.47% |
Dec 31, 2022 | 98.02M | -197.64M | -66.85% |
Dec 31, 2021 | 295.67M | 207.50M | 235.34% |
Dec 31, 2020 | 88.17M | -61.88M | -41.24% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
AGEN News
- 2 days ago - Analyst Upgrades Agenus As Zydus Deal Alleviates Cash Overhang - Benzinga
- 3 days ago - Agenus and Zydus Lifesciences Enter $141M Strategic Collaboration to Advance BOT/BAL, Expand Zydus' Biologics Manufacturing in the US - Business Wire
- 7 days ago - Agenus Presents New Data at ASCO Highlighting Botensilimab's Immune Activation in MSS Colorectal Cancer - Business Wire
- 14 days ago - Agenus: Big On BOT/BAL As Cash Burn And Catalysts Collide - Seeking Alpha
- 22 days ago - Agenus Announces New Data from Expanded MSS Metastatic Colorectal Cancer Cohort to be Presented at ESMO GI 2025 - Business Wire
- 25 days ago - Agenus Inc. (AGEN) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 25 days ago - Agenus Reports Q1 2025 Financial Results and Key Business Updates - Business Wire
- 25 days ago - Renowned GI Oncology Leader Dr. Richard Goldberg Joins Agenus as Chief Development Officer - Business Wire